Yes, AI can be used for regulatory medical writing, and in 2026 it is increasingly embedded in the workflows of medical affairs teams and regulatory functions across pharma and biotech. AI tools can accelerate drafting, structure complex scientific content, and surface relevant precedents from large document libraries. The technology works best as an augmentation layer for experienced medical writers, not as a replacement for their scientific and regulatory judgement. The sections below address the most important practical and strategic questions about how AI is being applied in this space.
What types of regulatory documents can AI help write?
AI can support the drafting of a wide range of regulatory documents, including clinical study reports (CSRs), investigator brochures, summary of product characteristics (SmPCs), patient information leaflets (PILs), benefit-risk assessments, regulatory responses, and sections of common technical documents (CTDs). The degree of AI involvement varies considerably by document type and the level of scientific interpretation required.
Structured, template-driven documents with relatively standardised formats tend to be the most productive territory for AI assistance. Sections that aggregate and summarise existing data — such as clinical overview narratives or literature synthesis components — benefit from AI’s ability to process large volumes of source material quickly. Documents that require nuanced scientific interpretation, risk-benefit judgement, or novel argumentation still demand experienced medical writers working at the centre of the process.
AI is also used not just for drafting but for formatting, cross-referencing, and quality checking within regulatory submissions. These more mechanical applications often carry lower risk and deliver meaningful efficiency gains without compromising scientific integrity.
How does AI actually generate regulatory medical content?
AI generates regulatory medical content primarily through large language models (LLMs) trained on vast corpora of scientific literature, clinical documents, and regulatory guidance. When a medical writer provides a prompt, the model draws on learned patterns to produce structured text that reflects the conventions of the document type requested. More specialised tools are fine-tuned on domain-specific regulatory content to improve accuracy and format adherence.
In practice, most AI-assisted regulatory writing workflows follow a retrieval-augmented generation (RAG) approach. Rather than relying solely on the model’s training data, the system retrieves relevant source documents — such as clinical study data, previous submissions, or regulatory guidelines — and uses these as grounding material for the generated content. This reduces the risk of hallucination and keeps outputs anchored to verified data.
Some platforms integrate directly with document management systems or clinical data repositories, allowing the AI to pull structured data and populate document templates with referenced content. The output is then reviewed, edited, and validated by the medical writer, who remains responsible for scientific accuracy and regulatory appropriateness throughout.
What are the biggest risks of using AI in regulatory submissions?
The biggest risks are hallucination, loss of scientific nuance, and accountability gaps. AI models can generate plausible-sounding but factually incorrect statements, misattribute data, or produce content that is structurally sound but scientifically misleading. In a regulatory context, these errors can have serious consequences for submission quality, patient safety, and relationships with regulatory agencies.
Beyond accuracy, there are several additional risk categories that organisations need to manage carefully:
- Data confidentiality: Inputting proprietary clinical data into third-party AI platforms raises significant IP and data privacy concerns, particularly under GDPR and equivalent frameworks.
- Accountability and authorship: Regulatory submissions require a named responsible party. AI-generated content complicates questions of authorship and professional accountability.
- Inconsistency across documents: AI tools used without strong governance may produce content that conflicts with language used elsewhere in a submission, creating internal contradictions that regulators may flag.
- Over-reliance and deskilling: Teams that lean too heavily on AI risk eroding the deep regulatory expertise needed to catch errors, challenge outputs, and handle complex queries from agencies.
Managing these risks requires clear internal policies, robust human review at every stage, and a governance framework that defines where AI can and cannot be used within the regulatory writing process.
Which AI tools are used for regulatory medical writing?
Several AI platforms are being used for regulatory medical writing in 2026, ranging from general-purpose LLMs adapted for pharma use to purpose-built regulatory intelligence tools. The most commonly referenced include general LLM platforms such as GPT-4 class models, alongside specialist tools designed specifically for life sciences document workflows.
Purpose-built platforms in this space typically offer template libraries aligned to ICH and regional regulatory formats, integration with clinical data systems, version control, and audit trail functionality. Some tools also include regulatory intelligence capabilities, helping writers identify relevant precedents from public submission databases or flag alignment with current guidance documents.
The right choice depends on the organisation’s infrastructure, data governance requirements, and the specific document types being produced. Many larger pharma companies are developing proprietary AI environments that keep sensitive clinical data within secure, controlled systems rather than routing it through public-facing platforms. Smaller biotechs and specialist agencies are more likely to work with commercial platforms, often with additional contractual data protection agreements in place.
How should medical writers validate AI-generated regulatory content?
Medical writers should validate AI-generated regulatory content through a structured review process that checks factual accuracy, source traceability, regulatory alignment, and internal consistency. Every claim in an AI-generated draft should be traceable to a verified source document, and the writer must confirm that the AI has not introduced unsupported statements, misrepresented data, or omitted important qualifications.
A practical validation framework typically includes the following steps:
- Source verification: Cross-reference all data points, figures, and citations against the original clinical documents or study reports.
- Regulatory format review: Confirm that the document structure and language conventions align with the relevant regulatory guidance (ICH, EMA, FDA, MHRA, or other applicable authority).
- Scientific accuracy check: Have a subject matter expert or medical reviewer assess whether the scientific interpretation is sound and appropriately nuanced.
- Internal consistency audit: Ensure that terminology, data, and conclusions are consistent across all sections of the submission.
- Quality and compliance sign-off: Apply the organisation’s standard document quality control and approval process before submission.
The critical principle is that AI generates a draft, not a final document. The medical writer’s expertise and professional responsibility remain central at every stage of the validation process.
What do regulators say about AI-generated medical documents?
Regulatory agencies including the EMA, FDA, and MHRA have not issued blanket prohibitions on AI-generated content in regulatory submissions, but they have been clear that the sponsor retains full responsibility for the accuracy, integrity, and quality of all submitted materials. In 2026, the regulatory position is broadly one of cautious engagement rather than formal endorsement or rejection.
The EMA has published reflection papers acknowledging AI’s growing role in drug development and data analysis, with guidance indicating that AI use should be transparent, documented, and subject to appropriate validation. The FDA has similarly signalled openness to AI in regulatory processes while emphasising the need for human oversight and clear accountability. Neither agency currently requires explicit disclosure of AI tool use in routine submissions, but internal audit trails and process documentation are increasingly expected as part of good regulatory practice.
The overarching message from regulators is consistent: AI can be a legitimate part of the regulatory writing process if it is used within a robust governance framework, with qualified professionals maintaining oversight and accountability throughout. Submissions that rely on AI without adequate human review and validation are unlikely to meet the quality standards regulators expect.
How we approach AI in medical communications
At Wizzard, our medical communications team works at the intersection of scientific rigour and strategic thinking, helping pharmaceutical companies, biotech organisations, and healthcare bodies produce content that is accurate, compliant, and genuinely useful to its audience. As AI becomes a more prominent part of the regulatory and medical affairs landscape, we bring considered expertise to questions of where and how AI tools can responsibly support the work. That means:
- Experienced in-house medical writers with deep regulatory and scientific knowledge
- Strategic input across medical affairs, market access, and commercial communications
- Support across document types including medical education, payer narratives, and expert engagement materials
- A commitment to accuracy, compliance, and communications that are clear, credible, and built to do a job
If you are working out how AI fits into your medical communications strategy, we are happy to talk it through. Get in touch with the Wizzard team to explore how experienced medical writers can help you get it right.